National Comprehensive Cancer Network



About NCCN

Neuroendocrine Tumors Panel - Disclosures as of 9/29/2010

View NCCN Management Team Disclosures | View NCCN Guidelines Staff Disclosures | View NCCN ORP Staff Disclosures

Panel Member Clinical Research Support Advisory Boards, Speakers Bureau, Expert Witness, or Consultant Patent, Equity, or Royalty Other Date Completed

Al B. Benson III, MD, FACP

None

Abbott Laboratories;
Amgen Inc.;
AstraZeneca Pharmaceuticals LP;
Bayer HealthCare;
Bristol-Myers Squibb Company;
Eli Lilly and Company;
Enzon Pharmaceuticals;
Genentech, Inc.;
General Electric;
Genomic Health, Inc.;
ImClone Systems Incorporated;
National Cancer Institute;
Novartis Pharmaceuticals Corporation;
Onyx Pharmaceuticals, Inc.;
Pfizer Inc.;
Roche Laboratories, Inc.;
sanofi-aventis U.S.;
Taiho Parmaceuticals Co., Ltd.

None

None

8/31/2012

Jordan D. Berlin, MD

None

Amgen Inc.;
AstraZeneca Pharmaceuticals LP;
Merck & Co., Inc.;
Agensys/Seattle Genetics;
Clovis;
Roche Laboratories, Inc.;
Schering-Plough Corporation

None

None

12/9/2012

Lawrence S. Blaszkowsky, MD

Genentech, Inc.

Bristol-Myers Squibb Company;
Pfizer Inc.

None

None

9/28/2011

Michael A. Choti, MD, MBA

None

Genentech, Inc.;
sanofi-aventis U.S.

None

None

2/12/2013

Orlo H. Clark, MD

None

None

None

None

3/8/2013

Gerard M. Doherty, MD

None

Novartis Pharmaceuticals Corporation

None

None

6/2/2011

Mary Dwyer, MS

None

None

None

None

3/26/2013

James Eason, MD

None

None

None

None

1/30/2012

Lyska Emerson, MD

None

None

None

None

8/9/2012

Paul F. Engstrom, MD, FACP

None

Novartis Pharmaceuticals Corporation

None

None

2/27/2013

Lauren Gallagher, RPh, PhD

None

None

None

None

6/5/2012

John F. Gibbs, MD, FACS, MHCM

None

None

None

None

12/7/2009

Kristina M. Gregory, RN, MSN, OCN

None

None

None

None

10/23/2012

Martin J. Heslin, MD

None

None

None

None

10/8/2012

Sara Javid, MD

None

None

None

None

9/8/2010

Fouad Kandeel, MD, PhD

None

Molecular Insights Pharmaceuticals

None

None

8/17/2012

Anne Kessinger, MD

Pharmacyclics;
sanofi-aventis U.S.

None

None

None

5/4/2011

Matthew H. Kulke, MD

None

Novartis Pharmaceuticals Corporation;
Ipsen;
Lexicon;
Pfizer Inc.

None

None

8/9/2012

Rashmi Kumar, PhD

None

None

None

None

2/15/2012

Pamela L. Kunz, MD

None

None

None

None

9/3/2012

Joan S. McClure, MS

None

None

None

None

7/23/2012

Jeffrey F. Moley, MD

None

None

None

None

10/8/2012

John A. Olson, MD, PhD

None

None

None

None

12/3/2009

Leonard Saltz, MD

None

Abbott Laboratories;
Celgene Corporation;
Exelixis Inc.;
Genentech, Inc.;
ImClone Systems Incorporated

None

None

8/27/2012

David E. Schteingart, MD

None

None

None

None

4/9/2012

Manisha H. Shah, MD

None

Novartis Pharmaceuticals Corporation

None

None

8/20/2012

Stephen Shibata, MD

None

Genentech, Inc.;
sanofi-aventis U.S.

None

None

6/22/2011

Jonathan R. Strosberg, MD

Pfizer Inc.

Endo Pharmaceuticals

None

None

11/9/2012

Jean-Nicolas Vauthey, MD

None

None

None

None

9/13/2012

James C. Yao, MD

None

National Cancer Institute;
Novartis Pharmaceuticals Corporation;
Endo;
Ipsen;
Pfizer Inc.

None

None

11/28/2012

 

About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved